Exosomes from umbilical cord stem cells reduce muscle loss and weakness linked to aging in mice

Declarations. Clinical trial number: Not applicable. Ethics approval and consent to participate: The commercially available UC-MSCs used in the present in vitro and in vivo experiments were provided by the Cord Blood and Umbilical Cord Bank of the Affiliated Hospital of Institute of Medical Sciences, University of Tokyo (IMSUT CORD, Tokyo). The animal study protocol (entitled hucMSCs therapy on sarcopenia; No. 2019-0352 approved on September 9, 2019) was approved by the Institutional Animal Care and Use Committees of by the Ethics Committee of Nagoya University and performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. The work has been reported in line with the ARRIVE guidelines 2.0. The original source (IMSUT CORD, Tokyo) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent (please see IMSUT CORD company's website: http://imsutcord.umin.jp/baby.html ). And a Material Transfer Agreement with the commercial vendor and the authors (Japanese form) available from the corresponding author upon request. Consent for publication: All authors agree to publish this version of the article. Artificial intelligence: The authors declare that they have not use AI-generated work in this manuscript. Competing interests: The authors declare that they have no conflicts of interest to disclose with respect to this manuscript.